BACKGROUND: Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation. Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates inflammation. METHODS: We selected 18 patients with neonatal-onset multisystem inflammatory disease (12 with identifiable CIAS1 mutations) to receive anakinra, an interleukin-1-receptor antagonist (1 to 2 mg per kilogram of body weight per day subcutaneously). In 11 patients, anakinra was withdrawn at three months until a flare occurred. The primary end points included changes in scores in a daily diary of symptoms, serum levels of amyloid A and C-reactive protein, and the erythrocyte sedimentation rate from baseline to month 3 and from month 3 until a disease flare. RESULTS: All 18 patients had a rapid response to anakinra, with disappearance of rash. Diary scores improved (P<0.001) and serum amyloid A (from a median of 174 mg to 8 mg per liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg per deciliter), and the erythrocyte sedimentation rate decreased at month 3 (all P<0.001), and remained low at month 6. Magnetic resonance imaging showed improvement in cochlear and leptomeningeal lesions as compared with baseline. Withdrawal of anakinra uniformly resulted in relapse within days; retreatment led to rapid improvement. There were no drug-related serious adverse events. CONCLUSIONS: Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with neonatal-onset multisystem inflammatory disease, with or without CIAS1 mutations. (ClinicalTrials.gov number, NCT00069329 [ClinicalTrials.gov].). Copyright 2006 Massachusetts Medical Society.
BACKGROUND: Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation. Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates inflammation. METHODS: We selected 18 patients with neonatal-onset multisystem inflammatory disease (12 with identifiable CIAS1 mutations) to receive anakinra, an interleukin-1-receptor antagonist (1 to 2 mg per kilogram of body weight per day subcutaneously). In 11 patients, anakinra was withdrawn at three months until a flare occurred. The primary end points included changes in scores in a daily diary of symptoms, serum levels of amyloid A and C-reactive protein, and the erythrocyte sedimentation rate from baseline to month 3 and from month 3 until a disease flare. RESULTS: All 18 patients had a rapid response to anakinra, with disappearance of rash. Diary scores improved (P<0.001) and serum amyloid A (from a median of 174 mg to 8 mg per liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg per deciliter), and the erythrocyte sedimentation rate decreased at month 3 (all P<0.001), and remained low at month 6. Magnetic resonance imaging showed improvement in cochlear and leptomeningeal lesions as compared with baseline. Withdrawal of anakinra uniformly resulted in relapse within days; retreatment led to rapid improvement. There were no drug-related serious adverse events. CONCLUSIONS: Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with neonatal-onset multisystem inflammatory disease, with or without CIAS1 mutations. (ClinicalTrials.gov number, NCT00069329 [ClinicalTrials.gov].). Copyright 2006 Massachusetts Medical Society.
Authors: Gulam A Manji; Lin Wang; Brad J Geddes; Melissa Brown; Sarah Merriam; Amal Al-Garawi; Simona Mak; Jose M Lora; Michael Briskin; Mark Jurman; Jie Cao; Peter S DiStefano; John Bertin Journal: J Biol Chem Date: 2002-01-10 Impact factor: 5.157
Authors: J-W Yu; J Wu; Z Zhang; P Datta; I Ibrahimi; S Taniguchi; J Sagara; T Fernandes-Alnemri; E S Alnemri Journal: Cell Death Differ Date: 2006-02 Impact factor: 15.828
Authors: J Wilkins; J R Gallimore; G A Tennent; P N Hawkins; P C Limburg; M H van Rijswijk; E G Moore; M B Pepys Journal: Clin Chem Date: 1994-07 Impact factor: 8.327
Authors: Steven C Hoffmann; Robert L Kampen; Shashi Amur; Muhammad A Sharaf; David E Kleiner; Keith Hunter; S John Swanson; Douglas A Hale; Roslyn B Mannon; Patrick J Blair; Allan D Kirk Journal: Transplantation Date: 2002-10-15 Impact factor: 4.939
Authors: Anna Simon; Heiyoung Park; Ravikanth Maddipati; Adrian A Lobito; Ariel C Bulua; Adrianna J Jackson; Jae Jin Chae; Rachel Ettinger; Heleen D de Koning; Anthony C Cruz; Daniel L Kastner; Hirsh Komarow; Richard M Siegel Journal: Proc Natl Acad Sci U S A Date: 2010-05-10 Impact factor: 11.205
Authors: Cailin H Sibley; Nikki Plass; Joseph Snow; Edythe A Wiggs; Carmen C Brewer; Kelly A King; Christopher Zalewski; H Jeffrey Kim; Rachel Bishop; Suvimol Hill; Scott M Paul; Patrick Kicker; Zachary Phillips; Joseph G Dolan; Brigitte Widemann; Nalini Jayaprakash; Frank Pucino; Deborah L Stone; Dawn Chapelle; Christopher Snyder; John A Butman; Robert Wesley; Raphaela Goldbach-Mansky Journal: Arthritis Rheum Date: 2012-07
Authors: Cecilia B Levandowski; Christina M Mailloux; Tracey M Ferrara; Katherine Gowan; Songtao Ben; Ying Jin; Kimberly K McFann; Paulene J Holland; Pamela R Fain; Charles A Dinarello; Richard A Spritz Journal: Proc Natl Acad Sci U S A Date: 2013-02-04 Impact factor: 11.205
Authors: Christopher A Lord; David Savitsky; Raquel Sitcheran; Kathryn Calame; Jo Rae Wright; Jenny Pan-Yun Ting; Kristi L Williams Journal: J Immunol Date: 2009-03-01 Impact factor: 5.422